论文部分内容阅读
[目的]观察125I粒子植入联合化疗治疗复发鼻咽癌的临床疗效。[方法]对60例患者分别行125I粒子植入联合化疗和单纯化疗,观察其治疗前后复发病灶和EB病毒抗体滴度、血沉(ESR)、不良反应变化情况。[结果]125I粒子植入联合化疗后的复发病灶CR 15例,PR 12例,SD 3例;对照组复发病灶CR 3例,PR 9例,SD 15例,PD 3例。125I粒子植入联合化疗组EB病毒抗体滴度下降27例,稳定3例;对照组下降12例,稳定15例,上升3例。125I粒子植入联合化疗组治疗前后ESR比较有显著性差异(P=0.029)。两组患者治疗前后不良反应无显著性差异。[结论]125I粒子植入联合化疗对复发鼻咽癌的局部控制率高,不良反应小,值得临床进一步推广。
[Objective] To observe the clinical efficacy of 125I seed implantation combined with chemotherapy in the treatment of recurrent nasopharyngeal carcinoma. [Method] Sixty patients were treated with 125I seed implantation combined with chemotherapy and chemotherapy alone. The titers of ESR, ESR and adverse reactions before and after treatment were observed. [Results] There were 15 cases of recurrent lesion after 125I seed implantation and chemotherapy, 12 cases of PR and 3 cases of SD. The control group had 3 cases of CR, 9 cases of PR, 15 cases of SD and 3 cases of PD. The antibody titer of Epstein-Barr virus (EBV) in 125I seeds combined with chemotherapy group was decreased in 27 cases and stabilized in 3 cases. The control group decreased in 12 cases and stabilized in 15 cases, increased in 3 cases. There was a significant difference in ESR between 125I seed implantation and chemotherapy group before and after treatment (P = 0.029). There was no significant difference in adverse reactions between the two groups before and after treatment. [Conclusion] 125I seed implantation combined with chemotherapy has a high local control rate for recurrent nasopharyngeal carcinoma with small adverse reactions, which is worth further promotion in clinic.